Big Phar­ma's in­creas­ing M&A en­thu­si­asm; Manchin, Schumer reach deal on drug pric­ing; Earn­ings re­caps; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

With Am­ber out on a well-de­served va­ca­tion this week, we’ve put this week’s re­port to­geth­er. It’s been a fast-paced week, abuzz with a litany of Q2 earn­ings calls that pro­vide an in­side look in­to the work­ings of Big Phar­ma. Thanks for read­ing, have a great week­end, and see you next week. — Kyle LaHu­cik and Paul Schloess­er

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER